Compare · NUWE vs OM
NUWE vs OM
Side-by-side comparison of Nuwellis Inc. (NUWE) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NUWE and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- OM is the larger of the two at $1.64B, about 139.9x NUWE ($11.7M).
- Over the past year, NUWE is down 97.2% and OM is down 61.1% - OM leads by 36.1 points.
- NUWE has been more active in the news (7 items in the past 4 weeks vs 6 for OM).
- OM has more recent analyst coverage (13 ratings vs 1 for NUWE).
- Company
- Nuwellis Inc.
- Outset Medical Inc.
- Price
- $1.16-0.43%
- $4.53-0.88%
- Market cap
- $11.7M
- $1.64B
- 1M return
- +4.50%
- +28.37%
- 1Y return
- -97.24%
- -61.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 7
- 6
- Recent ratings
- 1
- 13
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest NUWE
- Nuwellis Inc. filed SEC Form 8-K: Other Events
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
- Nuwellis Announces Aquadex Software Update
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
- Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
- SEC Form DEFA14A filed by Nuwellis Inc.
- SEC Form DEF 14A filed by Nuwellis Inc.
- Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)